SEARCH

SEARCH BY CITATION

References

  • 1
    Global Strategy for Asthma Management and Prevention. 2006. Ref type: internet communication.
  • 2
    British Guideline on the management of asthma. Thorax 2003;58(Suppl 1):1194.
  • 3
    Dahl R, Bjermer L. Nordic consensus report on asthma management. Nordic Asthma Consensus Group. Respir Med 2000;94:299327.
  • 4
    Larsson K, Carlsen KH, Bonini S. Anti-asthmatic drugs: treatment of athletes and exercise-induced bronchoconstriction. In: CarlsenKH, DelgadoL, Del GiaccoS, editors. Diagnosis, prevention and treatment of exercise-related asthma, respiratory and allergic disorders in sports. Sheffield, UK: European Respiratory Journals Ltd, 2005:7388.
  • 5
    Henriksen JM, Dahl R. Effects of inhaled budesonide alone and in combination with low-dose terbutaline in children with exercise-induced asthma. Am Rev Respir Dis 1983;128:993997.
  • 6
    Subbarao P, Duong M, Adelroth E, Otis J, Obminski G, Inman M et al. Effect of ciclesonide dose and duration of therapy on exercise-induced bronchoconstriction in patients with asthma. J Allergy Clin Immunol 2006;117:10081013.
  • 7
    Waalkens HJ, Van Essen-Zandvliet EE, Gerritsen J, Duiverman EJKK, Knol K. The effect of an inhaled corticosteroid (budesonide) on exercise-induced asthma in children. Dutch CNSLD Study Group. Eur Respir J 1993;6:652656.
  • 8
    Van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, Duiverman EJ, Pocock SJ, Kerrebijn KF. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-Specific Lung Disease Study Group. Am Rev Respir Dis 1992;146:547554.
  • 9
    Jonasson G, Carlsen KH, Hultquist C. Low-dose budesonide improves exercise-induced bronchospasm in schoolchildren. Pediatr Allergy Immunol 2000;11:120125.
  • 10
    Sue-Chu M, Karjalainen EM, Laitinen A, Larsson L, Laitinen LA, Bjermer L. Placebo-controlled study of inhaled budesonide on indices of airway inflammation in bronchoalveolar lavage fluid and bronchial biopsies in cross-country skiers. Respiration 2000;67:417425.
  • 11
    Egan JJ, Maden C, Kalra S, Adams JE, Eastell R, Woodcock AA. A randomized, double-blind study comparing the effects of beclomethasone and fluticasone on bone density over two years. Eur Respir J 1999;13:12671275.
  • 12
    Priftis KN, Papadimitriou A, Gatsopoulou E, Yiallouros PK, Fretzayas A, Nicolaidou P. The effect of inhaled budesonide on adrenal and growth suppression in asthmatic children. Eur Respir J 2006;27:316320.
  • 13
    Todd GR, Acerini CL, Buck JJ, Murphy NP, Ross-Russell R, Warner JT et al. Acute adrenal crisis in asthmatics treated with high-dose fluticasone propionate. Eur Respir J 2002;19:12071209.
  • 14
    Todd GR, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002;87:457461.
  • 15
    Drake AJ, Howells RJ, Shield JP, Prendiville A, Ward PS, Crowne EC. Symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone propionate. BMJ 2002;324:10811082.
  • 16
    Drake AJ, Howells RJ, Shield JPH, Prendiville A, Ward PS, Crowne EC et al. Lesson of the week: symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone propionate *Commentary: exogenous glucocorticoids influence adrenal function, but assessment can be difficult. BMJ 2002;324:10811083.
  • 17
    Tinkelman DG, Reed CE, Nelson HS, Offord KP. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 1993;92:6477.
  • 18
    Doull IJ, Campbell MJ, Holgate ST. Duration of growth suppressive effects of regular inhaled corticosteroids. Arch Dis Child 1998;78:172173.
  • 19
    Doull IJM, Freezer NJ, Holgate ST, Doull IJ. Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med 1995;151:17151719.
  • 20
    Allen DB, Bronsky EA, LaForce CF, Nathan RA, Tinkelman DG, Vandewalker ML et al. Growth in asthmatic children treated with fluticasone propionate. Fluticasone Propionate Asthma Study Group. J Pediatr 1998;132(3 Pt 1):472477.
  • 21
    Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000;343:10641069.
  • 22
    Boot AM, De Jongste JC, Verberne AA, Pols HA, De Muinck K. Bone mineral density and bone metabolism of prepubertal children with asthma after long-term treatment with inhaled corticosteroids. Pediatr Pulmonol 1997;24:379384.
  • 23
    Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999;159:941955.
  • 24
    Robuschi M, Riva E, Fuccella LM, Vida E, Barnabe R, Rossi M et al. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104353). A double-blind study versus disodium cromoglycate and placebo. Am Rev Respir Dis 1992;145:12851288.
  • 25
    Meltzer SS, Hasday JD, Cohn J, Bleecker ER. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 1996;153:931935.
  • 26
    Kemp JP, Dockhorn RJ, Shapiro GG, Nguyen HH, Reiss TF, Seidenberg BC et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 1998;133:424428.
  • 27
    Leff JA, Busse WW, Pearlman D, Bronsky E, Kemp J, Hendeles L et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998;339:147152.
  • 28
    Melo RE, Sole D, Naspitz CK. Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate-phase and late-phase responses. J Allergy Clin Immunol 2003;111:301307.
  • 29
    Villaran C, O’Neill SJ, Helbling A, Van Noord JA, Lee TH, Chuchalin AG et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. J Allergy Clin Immunol 1999;104(3 Pt 1):547553.
  • 30
    De Benedictis FM, Del Giudice MM, Forenza N, Decimo F, De BD, Capristo A. Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children. Eur Respir J 2006;28:291295.
  • 31
    Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005;115:233242.
  • 32
    Helenius I, Lumme A, Ounap J, Obase Y, Rytila P, Sarna S et al. No effect of montelukast on asthma-like symptoms in elite ice hockey players. Allergy 2004;59:3944.
  • 33
    Rundell KW, Spiering BA, Baumann JM, Evans TM. Effects of montelukast on airway narrowing from eucapnic voluntary hyperventilation and cold air exercise. Br J Sports Med 2005;39:232236.
  • 34
    Steinshamn S, Sandsund M, Sue-Chu M, Bjermer L. Effects of montelukast on physical performance and exercise economy in adult asthmatics with exercise-induced bronchoconstriction. Scand J Med Sci Sports 2002;12:211217.
  • 35
    Kelly K, Spooner CH, Rowe BH. Nedocromil sodium vs. sodium cromoglycate for preventing exercise-induced bronchoconstriction in asthmatics (Cochrane Review). Cochrane Database Syst Rev 2000;CD002731.
  • 36
    De Benedictis FM, Tuteri G, Pazzelli P, Bertotto A, Bruni L, Vaccaro R. Cromolyn versus nedocromil: duration of action in exercise-induced asthma in children. J Allergy Clin Immunol 1995;96:510514.
  • 37
    Brannan JD, Gulliksson M, Anderson SD, Chew N, Seale JP, Kumlin M. Inhibition of mast cell PGD2 release protects against mannitol-induced airway narrowing. Eur Respir J 2006;27:944950.
  • 38
    Anderson SD, Seale JP, Rozea P, Bandler L, Theobald G, Lindsay DA. Inhaled and oral salbutamol in exercise-induced asthma. Am Rev Respir Dis 1976;114:493500.
  • 39
    Konig P, Eggleston PA, Serby CW. Comparison of oral and inhaled metaproterenol for prevention of exercise-induced asthma. Clin Allergy 1981;11:597604.
  • 40
    Shapiro GG, Kemp JP, DeJong R, Chapko M, Bierman CW, Altman LCFC et al. Effects of albuterol and procaterol on exercise-induced asthma. Ann Allergy 1990;65:273276.
  • 41
    Anderson SD, Rodwell LT, Du Toit J, Young IH. Duration of protection by inhaled salmeterol in exercise-induced asthma. Chest 1991;100:12541260.
  • 42
    Carlsen KH, Røksund O, Olsholt K, Njå F, Leegaard J, Bratten G. Overnight protection by inhaled salmeterol on exercise-induced asthma in children. Eur Respir J 1995;8:18521855.
  • 43
    Boner AL, Spezia E, Piovesan P, Chiocca E, Maiocchi G. Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children. Am J Respir Crit Care Med 1994;149:935939.
  • 44
    Simons FE, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 1997;99:655659.
  • 45
    Nelson JA, Strauss L, Skowronski M, Ciufo R, Novak R, McFadden ER Jr. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med 1998;339:141146.
  • 46
    Davis BE, Reid JK, Cockcroft DW. Formoterol thrice weekly does not result in the development of tolerance to bronchoprotection. Can Respir J 2003;10:2326.
  • 47
    Anderson SD, Caillaud C, Brannan JD. beta2-agonists and exercise-induced asthma. Clin Rev Allergy Immunol 2006;31:163180.
  • 48
    Salpeter SR, Ormiston TM, Salpeter EE. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med 2004;140:802813.
  • 49
    Salpeter SR. Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review. Drugs Aging 2004;21:405414.
  • 50
    Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:1526.
  • 51
    Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting {beta}-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006;144:904912.
  • 52
    Chinchilli VM. General principles for systematic reviews and meta-analyses and a critique of a recent systematic review of long-acting beta-agonists. J Allergy Clin Immunol 2007;119:303306.
  • 53
    Boner AL, Vallone G, De SG. Effect of inhaled ipratropium bromide on methacholine and exercise provocation in asthmatic children. Pediatr Pulmonol 1989;6:8185.
  • 54
    Boulet LP, Turcotte H, Tennina S. Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the prevention of bronchospasm induced by exercise and hyperosmolar challenges. J Allergy Clin Immunol 1989;83:882887.
  • 55
    Greenough A, Yuksel B, Everett L, Price JF. Inhaled ipratropium bromide and terbutaline in asthmatic children. Respir Med 1993;87:111114.
  • 56
    Freeman W, Javaid A, Cayton RM. The effect of ipratropium bromide on maximal exercise capacity in asthmatic and non-asthmatic men. Respir Med 1992;86:151155.
  • 57
    Papalia SM. Aspects of inhaled budesonide use in asthma and exercise Department of Human Movement, University of Western Australia. Thesis, 1996.
  • 58
    Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE. Systemic effects of formoterol and salmeterol: a dose–response comparison in healthy subjects. Thorax 2000;55:650656.
  • 59
    Signorile JF, Kaplan TA, Applegate B, Perry AC. Effects of acute inhalation of the bronchodilator, albuterol, on power output. Med Sci Sports Exerc 1992;24:638642.
  • 60
    Van Baak MA, De Hon OM, Hartgens F, Kuipers H. Inhaled salbutamol and endurance cycling performance in non-asthmatic athletes. Int J Sports Med 2004;25:533538.
  • 61
    Heir T, Stemshaug H. Sabutamol and high-intensity treadmill running in nonasthmatic highly conditioned athletes. Scand J Med Sci Sports 1995;5:231236.
  • 62
    Carlsen KH, Ingjer F, Thyness B, Kirkegaard H. The effect of inhaled salbutamol and salmeterol on lung function and endurance performance in healthy well-trained athletes. Scand J Med Sci Sports 1997;7:160165.
  • 63
    Sue-Chu M, Sandsund M, Helgerud J, Reinertsen RE, Bjermer L. Salmeterol and physical performance at −15°C in highly trained nonasthmatic cross-country skiers. Scand J Med Sci Sports 1999;9:4852.
  • 64
    Tjørhom A, Riiser A, Carlsen KH. Effects of formoterol on endurance performance in athletes at an ambient temperature of −20°C. Scand J Med Sci Sports 2007; in press.
  • 65
    Riiser A, Tjorhom A, Carlsen KH. The effect of formoterol inhalation on endurance performance in hypobaric conditions. Med Sci Sports Exerc 2006;38:21322137.
  • 66
    Criswell DS, Powers SK, Herb RA. Clenbuterol-induced fiber type transition in the soleus of adult rats. Eur J Appl Physiol Occup Physiol 1996;74:391396.
  • 67
    Dodd SL, Powers SK, Vrabas IS, Criswell D, Stetson S, Hussain R. Effects of clenbuterol on contractile and biochemical properties of skeletal muscle. Med Sci Sports Exerc 1996;28:669676.
  • 68
    Suzuki J, Gao M, Xie Z, Koyama T. Effects of the beta(2)-adrenergic agonist clenbuterol on capillary geometry in cardiac and skeletal muscles in young and middle-aged rats. Acta Physiol Scand 1997;161:317326.
  • 69
    Hayes A, Williams DA. Contractile properties of clenbuterol-treated mdx muscle are enhanced by low-intensity swimming. J Appl Physiol 1997;82:435439.
  • 70
    Lynch GS, Hayes A, Campbell SP, Williams DA. Effects of beta 2-agonist administration and exercise on contractile activation of skeletal muscle fibers. J Appl Physiol 1996;81:16101618.
  • 71
    Duncan ND, Williams DA, Lynch GS. Deleterious effects of chronic clenbuterol treatment on endurance and sprint exercise performance in rats. Clin Sci (Lond) 2000;98:339347.
  • 72
    Van Der Heijden HF, Zhan WZ, Prakash YS, Dekhuijzen PN, Sieck GC. Salbutamol enhances isotonic contractile properties of rat diaphragm muscle. J Appl Physiol 1998;85:525529.
  • 73
    Buchanan R, Nielsen OB, Clausen T. Excitation- and beta(2)-agonist-induced activation of the Na(+)-K(+) pump in rat soleus muscle. J Physiol 2002;1:229240.
  • 74
    Violante B, Pellegrino R, Vinay C, Selleri R, Ghinamo G. Failure of aminophylline and salbutamol to improve respiratory muscle function and exercise tolerance in healthy humans. Respiration 1989;55:227236.
  • 75
    Javaheri S, Smith JT, Thomas JP, Guilfoile TD, Donovan EF. Albuterol has no effect on diaphragmatic fatigue in humans. Am Rev Respir Dis 1988;137:197201.
  • 76
    Rolett EL, Strange S, Sjogaard G, Kiens B, Saltin B. Beta 2-adrenergic stimulation does not prevent potassium loss from exercising quadriceps muscle. Am J Physiol 1990;258(5 Pt 2):R1192R1200.
  • 77
    Lanigan C, Howes TQ, Borzone G, Vianna LG, Moxham J. The effects of beta 2-agonists and caffeine on respiratory and limb muscle performance. Eur Respir J 1993;6:11921196.
  • 78
    Caruso JF, Signorile JF, Perry AC, Leblanc B, Williams R, Clark M et al. The effects of albuterol and isokinetic exercise on the quadriceps muscle group. Med Sci Sports Exerc 1995;27:14711476.
  • 79
    Van Baak MA, Mayer LH, Kempinski RE, Hartgens F. Effect of salbutamol on muscle strength and endurance performance in nonasthmatic men. Med Sci Sports Exerc 2000;32:13001306.
  • 80
    Collomp K, Candau R, Millet G, Mucci P, Borrani F, Prefaut C et al. Effects of salbutamol and caffeine ingestion on exercise metabolism and performance. Int J Sports Med 2002;23:549554.
  • 81
    Suzuki J, Suzuki S, Okubo T. Effects of fenoterol on inspiratory effort sensation and fatigue during inspiratory threshold loading. J Appl Physiol 1996;80:727733.
  • 82
    Meeuwisse WH, McKenzie DC, Hopkins SR, Road JD. The effect of salbutamol on performance in elite nonasthmatic athletes. Med Sci Sports Exerc 1992;24:11611166.
  • 83
    Morton AR, Papalia SM, Fitch KD. Changes in anaerobic power and strength performance after inhalation of salbutamol in nonasthmatic athletes. Clin J Sport Med 1993;3:1419.
  • 84
    Lemmer JT, Fleck SJ, Wallach JM, Fox S, Burke ER, Kearney JT et al. The effects of albuterol on power output in non-asthmatic athletes. Int J Sports Med 1995;16:243249.
  • 85
    Morton AR, Joyce K, Papalia SM, Carroll NG, Fitch KD. Is salmeterol ergogenic? Clin J Sport Med 1996;6:220225.
  • 86
    McDowell SL, Fleck SJ, Storms WW. The effects of salmeterol on power output in nonasthmatic athletes. J Allergy Clin Immunol 1997;99:443449.
  • 87
    Bedi JF, Gong H Jr, Horvath SM. Enhancement of exercise performance with inhaled albuterol. Can J Sport Sci 1988;13:144148.
  • 88
    Morton AR, Papalia SM, Fitch KD. Is salbutamol ergogenic? The effects of salbutamol on physical performance in the high-performance nonasthmatic athletes. Clin J Sport Med 1992;2:9397.
  • 89
    Fleck SJ, Lucia A, Storms WW, Wallach JM, Vint PF, Zimmerman SD. Effects of acute inhalation of albuterol on submaximal and maximal VO2 and blood lactate. Int J Sports Med 1993;14:239243.
  • 90
    Unnithan VB, Thomson KJ, Aitchison TC, Paton JY. β2-agonists and running economy in prepubertal boys. Pediatr Pulmonol 1994;17:378382.
  • 91
    Norris SR, Petersen SR, Jones RL. The effect of salbutamol on performance in endurance cyclists. Eur J Appl Physiol Occup Physiol 1996;73:364368.
  • 92
    Larsson K, Gavhed D, Larsson L, Holmer I, Jorfelt L, Ohlsen P. Influence of a beta2-agonist on physical performance at low temperature in elite athletes. Med Sci Sports Exerc 1997;29:16311636.
  • 93
    Sandsund M, Sue-Chu M, Helgerud J, Reinertsen RE, Bjermer L. Effect of cold exposure (−15°C) and salbutamol treatment on physical performance in elite nonasthmatic cross-country skiers. Eur J Appl Physiol 1998;77:297304.
  • 94
    Goubault C, Perault MC, Leleu E, Bouquet S, Legros P, Vandel B et al. Effects of inhaled salbutamol in exercising non-asthmatic athletes. Thorax 2001;56:675679.
  • 95
    Carlsen KH, Hem E, Stensrud T, Held T, Herland K, Mowinckel P. Can asthma treatment in sports be doping? The effect of the rapid onset, long-acting inhaled β2-agonist formoterol upon endurance performance in healthy well-trained athletes. Respir Med 2001;95:571576.
  • 96
    Stewart IB, Labreche JM, McKenzie DC. Acute formoterol administration has no ergogenic effect in nonasthmatic athletes. Med Sci Sports Exerc 2002;34:213217.